Hydromorphone
Table 8.2B Opiates Drug Diacetylmorphine Heroin ; Methadone Dolophine ; Designer opiates: Fentanyl Sublimaze ; , Sufentanil Sufenta ; , Alfentanil Alfenta ; Propoxyphene Darvon ; High mortality, sudden death reported, convulsions and cardia arrhythmias due to metabolite norpropoxyphene ; , fat soluble so may have prolonged duration of action Pentazocine Talwin ; codeine Meperidine Demerol ; Hydromorphone Dilaudid ; Morphine MS-contin ; Agonist-antagonist, dysphoria, no cases of pulmonary edema reported serotonin releasing effects Synthetic opiate assoicated with seizures in large doses due to metabolite normeperidine ; Similar to morphine but more potent and shorter duration of action Sustained-release, oral chewing converts to rapidly acting agents As with heroin. Prolonged observatin required after overdose. As with heroin. As with heroin. May be resistant to naloxone overdoes than other opiates, check acetaminophen level if codeine ingested As with heroin. Unique characteristics Prototype opiate of abuse, rapidly metabolized to morphine, more lipid soluble Slow onset and long duration of action half-life 15-72 h ; Most potent opiates 16-700X morphine ; , with rapid onset and short duration of action minutes ; Key management issues Respiratory depression, coma, anoxic encephalopathy, pulmonary edema, withdrawal, compartment sydromes. As with heroin. May require a naloxone infusion see below ; and prolonged monitoring As with heroin. May accumulate in body fat necessitating observations periods similar to heroin overdose 12 h ; may see negative screen for opiates As with heroin. Prolonged observation requried after overdose. Wide complex tachycardia mya respond to bicarbonate, may be resistant to naloxone, check acetaminophen level.
Outpatient treatment The patient received treatment for diabetes and obesity at our outpatient clinic as well as continuing antihypertensive treatment at the office of her own doctor. Diet therapy 1, 500 kcal day ; was initiated with the assistance of dietitians in our hospital. Intensive insulin therapy was begun, while oral antidiabetic therapy was discontinued. In June 1997, although the HbA1C value decreased to 6.6% and body weight to 96.5 kg, her blood pressure remained at 163 96 mmHg, an insufficient decrease on antihypertensive therapy. Her condition began to worsen around this period, and the values of HbA1C, body weight, and blood pressure increased to 7.0%, 102.5 kg, 172 99 mmHg, respectively, in March 1998. Since the patient claimed that she was reaching the limits of her effort, a very-lowcalorie diet VLCD ; program was attempted.
Fit to experimental data An estimate of the parameters is made by fitting the model to the data in asymmetric solutions of the same ion. Figure 11 shows a fit of the model to an asymmetric case of KCl, 10 1 in concentration. In fitting the model to the data of Fig. 11, we put.
Merrimack College is a selective, independent, four-year Augustinian Catholic college offering liberal arts, business, science and engineering programs in a residential setting. Located on 220-acres in North Andover, Massachusetts, just 25 miles north of Boston, Merrimack has a student body of 2, 000 students. Merrimack offers 30 major areas of study, including digital media arts, sports medicine, and international business. The first priority of Merrimack's distinguished faculty is teaching a talented student body in a learning environment vigorously committed to the transforming of virtues and benefits of the liberal arts. Merrimack's contemporary academic approach of fusing the liberal arts with professional training means students become engaged and ready to make critical, moral, and informed decisions of thought, communication, and action in their own lives and in service to others. In the Augustinian tradition, the Merrimack community focuses on scholarship and service to others, and provides students a variety of opportunities to develop intellectually, spiritually, socially, and ethically. For the sixth consecutive year, Merrimack has been named a top ten regional school in 2006 U.S. News & World Report's Best College Guide. Ranked seventh as a Best Comprehensive College Bachelor's in the north, Merrimack has been a top tier regional school for nine consecutive years in its America's Best Colleges issue. Merrimack College has a 12-to-1 student to faculty ratio, allowing students and professors to work closely together both inside and outside the classroom. Merrimack also offers a master's degree program in education and a part-time associate and bachelor degree, a variety of certificate programs including financial management and human resource management. To prepare students for the ever-changing marketplace, Merrimack College offers a co-operative education opportunities for all majors, study abroad programs, double degree programs, internships, off-campus practicums, and more. Student life at Merrimack offers a wide range of cultural, educational, and intramural programs as well as many opportunities for community service and civic engagement. Sixteen varsity sports for men and women are offered, which include 15 Division II sports and Division I men's hockey. Students from 28 states and 17 countries, approximately 80% of whom reside on campus, enjoy living and learning at Merrimack College.
In the Tao, the sources of longevity and immortality are within the body, not as a physical womb but a spiritual one. Taoists call this spiritual womb the "cauldron". The right method to "cook the cauldron" is not to search outwardly for love from others, but to search within the naked and abandoned self. Self-love, or self-intercourse is the way to give birth to the Immortal Self. The Darkness manifests the bodily processes of "Healing Love." The human states of true compassion and sexual arousal create a new chemistry and a new vibration within the body. This `special' vibration occurs at a frequency of 8Hz. `As in the macrocosm, so it is in the microcosm'; hence if we make love, then all the cells and DNA actually make love as well. The DNA crosses over, like two serpents intertwined in an erotic embrace. You need the orgasmic vibration to arouse this crossover process which leads to the `two giving birth to three'; the conception of new cells. The two vital states are compassion and arousal leading to orgasm. Both are inextricably linked to love.
Determine how the probability of receiving a COX-2 selective NSAID varies with risk factors for serious gastrointestinal Gl ; complications including: age, history of a previous GI complication, arthritis diagnosis, and prior use of oral steroids. Coefficients from logistic regression are then used to adjust for differences in physicians' case-mix when examining their propensity to prescribe COX-2 se1ective NSAIDs. RESULTS: We report the probabi1ity of receiving a prescription for a COX-2 selective NSAID in relation to: age, arthritis diagnosis, prior GI and hydroxychloroquine.
Manner." Therefore, HERB respectfully requests that DHHS' Advisory Committee on Blood Safety and Availability, possibly in partnership with the FDA, issue a statement to third party payers. This statement should underscore the fact that any reversal to the use of plasmaderived monoclonal products during this shortage is done of necessity and does NOT represent the treatment of choice. This statement could be distributed to third party payers by advocacy organizations, home care companies, and HTCs to be made available on an as needed basis. Another alternative would be to have DHHS and FDA distribute such a statement to the network of third party payers. Included in these recommendations are FOUR quoted recommendations from the August 28, 1998, meeting of DHHS' Advisory Committee on Blood Safety and Availability. This discussion has been going on for almost two years and we are now in the worst Factor 8 recombinant shortage ever. What will it take to accomplish the task?.
Hydromorphone cure
In this case the splitting ratio is independent of Vsplit which means that the filling of the ITP capillary with terminating buffer is not influencing the splitting ratio. It should be noted that the current I2 Fig. 2a ; can become negative. When V2 approaches V1 and V2 Vsplit then the direction of the current is reversed, the ions will migrate in the opposite direction and the ITP conditions no longer exist. Just before that, when V2 Vsplit, the current ratio I2 I3 0 which means that theoretically 100% of the analyte will migrate into the CZE. However, in this case small changes in the voltage will cause large differences in splitting ratio. In our experiments the splitting ratio is considerably lower to prevent overloading of the CZE system and to have a reproducible of the splitting ratio. The capillary resistance R can be calculated from: R L r2 and hydroxyurea.
Hydromorphone information
Brand name: dilaudid generic name: hydromorphone hydrochloride next: dilaudid - overdosage & contraindications » « previous: dilaudid - side effects & drug interactions « previous 1 2 3 next » - webmd resources back pain: 10 questions you should ask how safe are your painkillers.
Gold-mining area. Special thanks also to Dr. A. Caraballo, former Director of Investigation of Endemic Diseases of the "Dr. Jos Gregorio Hernndez" Hospital in Tumeremo, for his sound and professional advice throughout the project. We express our gratitude to the Institute of Immunology of the Central University of Venezuela for processing the blood samples. Special thanks also go to the executive personnel of Placer Dome for their moral and financial support. Contrasida thanks all the community leaders in the gold-mining area for their wholehearted support. Lastly, we thank Dr. Yon Fleerackers of the Tropical Institute of Antwerp for his support in designing the epidemiological study and ibandronate.
FIG. 8 Multiple stimuli activate pro-AR ectodomain cleavage, which can be inhibited by the metalloprotease inhibitor BB-94. MDCK-AR cells grown on Transwell filters were cell surface-biotinylated and chased for 30 min in the presence of control, stimulus, BB-94, or stimulus and BB-94. The stimuli presented include phorbol ester 1 M phorbol 12-myristate 13-acetate PMA , tyrosine phosphatase inhibitor 100 M pervanadate PV , and calcium ionophore 25 M A23187 ; . Total cell lysates data not shown ; and the conditioned medium were immunoprecipitated with AR mAb. Immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose, and probed with horseradish peroxidase-conjugated streptavidin. AR immunoreactivity was detected using an ECL Western blotting kit in combination with fluorography. Only results for soluble AR released into the basolateral conditioned medium are shown. Arrowheads indicate the various AR forms, and molecular masses are indicated in kilodaltons. The asterisk designates cell-surface 50-kDa pro-AR that is probably shed from cell membranes!
Avoiding & managing side effects PDF [3.8 Mb ] Aug 02 Changing treatment: second line & salvage therapy PDF [284 Kb] Aug 02 Introduction to combination therapy PDF [236 Kb] Aug 02 and ibritumomab.
Jective effect measures produced clearer differentiation among the test drugs than did drug discrimination performance. The present results differ from those of a previous study that observed a close relationship between the results of the discrimination measure and subjective effect measures. The previous study used similar methods and test drugs but different training drugs e.g., 3 mg of hydromorphone versus 6 mg of butorphanol versus saline ; . It appears that both the sensitivity of drug discrimination performance to between-drug differences and the relationship between discriminative and subjective effects depends upon the specific discrimination that is trained e.g., two-choice or three-choice ; . The present high dose-low dosesaline discrimination procedure appears useful for assessing partial agonist activity. The present data are consistent with partial agonist activity for pentazocine, butorphanol, nalbuphine, and buprenorphine.
Hydromorphone treatment
High doses of vitamin D up to 100, 000 IU per day ; have been safely used during pregnancy56, 57 periodic testing of serum calcium is required to monitor and for hypercalcemia. Vitamin D supplementation has been proven effective in the treatment of hypertension, depression, migraine headaches, polycystic ovary syndrome and in the prevention of cancer and type-1 diabetes. 55 Figure 2. Normal and optimal ranges for serum 25 OH ; vitamin D levels based on current research and idarubicin.
Risk Management Programs RMPs ; are developed by drug manufacturers to meet the requirements of FDA's drug approval process, in conjunction with FDA, to minimize risks associated with specific drug products. To date, several specific drug products have formal risk management programs beyond labeling alone, to further ensure patient safety. Two relevant examples are Accutane Roche Pharmaceuticals ; and Palladone Capsules Purdue Pharma LP ; . Accutane On November 23, 2004, FDA announced changes to the RMP for isotretinoin Accutane ; that will be implemented in mid-2005 in order to reduce the risk of birth defects associated with fetal exposure to the medication. All of the manufacturers of isotretionin have entered into an agreement with Covance, a drug development services company that currently coordinates the registry for Celgene's thalidomide. Covance's task is to develop and operate a universal enhanced RMP by mid 2005; this program will require patients, dispensing pharmacists, and prescribers to register in a single, centralized clearinghouse. The program will also mandate that a pregnancy test be performed at certified laboratories instead of home or in-office testing. According to the Accutane RMP, System to Manage Accutane Related Teratogenicity, when the registry denies an authorization to fill the prescription, the prescribing physician must explain the reason for denial to the patient; FDA specifically states that the physician is responsible for informing a woman if a pregnancy test result comes back positive. Palladone Due to Palladone's hydromorphone hydrochloride ; high potential for abuse and respiratory depression, the drug's manufacturer, Purdue Pharma LP, in conjunction with FDA, developed an RMP for this new extended-release analgesic. Introduced to the market in January 2005, Palladone is approved for the management of persistent, moderate to severe pain in patients requiring continuous, around-the-clock analgesia with a high potency opioid for an extended period of time weeks to months ; or longer. Palladone is to be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a minimum total daily dose of opiate medication equivalent to 12 mg of oral hydromorphone. The analgesic's RMP was devised with four goals: 1. Facilitation of proper use patient selection, dosing ; 2. Avoidance of pediatric exposure 3. Minimization of abuse, and 4. Reduction of diversion Palladone's RMP includes provisions for understandable and appropriate labeling, and proper education of health care professionals, patients, and caregivers. In addition, the manufacturer has offered training sessions to its sales representatives. The RMP provides for the observation and surveillance of abuse and, if abuse, misuse, and or diversion occur, this program includes an array of interventions. A Medication Guide will be distributed to patients prescribed Palladone. During the initial 18 months of Palladone's release to the market, the manufacturer will only promote Palladone to a limited number of medical practitioners experienced in prescribing opioid analgesics and will closely monitor and gather data on Palladone's use and any incidences of abuse or diversion, and report this information to FDA on a regular basis.
Group 2 hp ; received hydromorphone and propofol and ifex.
FOR USE IN OPIOID-TOLERANT PATIENTS ONLY DURAGESIC contains a high concentration of a potent Schedule II opioid agonist, fentanyl. Schedule II opioid substances which include fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone have the highest potential for abuse and associated risk of fatal overdose due to respiratory depression. Fentanyl can be abused and is subject to criminal diversion. The high content of fentanyl in the patches DURAGESIC ; may be a particular target for abuse and diversion. DURAGESIC is indicated for management of persistent, moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediaterelease opioids DURAGESIC should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to DURAGESIC 25 mcg h. Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could occur, DURAGESIC fentanyl transdermal system ; is contraindicated: in patients who are not opioid-tolerant in the management of acute pain or in patients who require opioid analgesia for a short period of time in the management of post-operative pain, including use after out-patient or day surgeries e.g., tonsillectomies ; in the management of mild pain in the management of intermittent pain [e.g., use on an as needed basis prn ; ] See CONTRAINDICATIONS for further information. ; Since the peak fentanyl levels occur between 24 and 72 hours of treatment, prescribers should be aware that serious or life threatening hypoventilation may occur, even in opioid-tolerant patients, during the initial application period. The concomitant use of DURAGESIC with all cytochrome P450 3A4 inhibitors such as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, amiodarone, amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil ; may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Patients receiving DURAGESIC and any CYP3A4 inhibitor should be carefully monitored for an extended period of time and dosage adjustments should be made if warranted see CLINICAL PHARMACOLOGY Drug Interactions, WARNINGS, PRECAUTIONS, and DOSAGE AND ADMINISTRATION for further information ; . The safety of DURAGESIC has not been established in children under 2 years of age. DURAGESIC should be administered to children only if they are opioid-tolerant and 2 years of age or older see PRECAUTIONS - Pediatric Use ; . DURAGESIC is ONLY for use in patients who are already tolerant to opioid therapy of comparable potency. Use in non-opioid tolerant patients may lead to fatal respiratory depression. Overestimating the DURAGESIC dose when converting patients from another opioid medication can result in fatal overdose with the first dose. Due to the mean elimination half-life of 17 hours of DURAGESIC, patients who are thought to have had a serious adverse event, including overdose, will require monitoring and treatment for at least 24 hours. DURAGESIC can be abused in a manner similar to other opioid agonists, legal or illicit. This risk should be considered when administering, prescribing, or dispensing DURAGESIC in situations where the healthcare professional is concerned about increased risk of misuse, abuse, or diversion. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse including drug or alcohol abuse or addiction ; or mental illness e.g., major depression ; . Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. All patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Patients at increased risk of opioid abuse may still be appropriately treated with modified-release opioid formulations; however, these patients will require intensive monitoring for signs of misuse, abuse, or addiction. DURAGESIC patches are intended for transdermal use on intact skin ; only. Do not use a DURAGESIC patch if the seal is broken or the patch is cut, damaged, or changed in any way. Using a patch that is cut, damaged, or changed in any way can expose the patient or caregiver to the contents of the patch, which can result in an overdose of fentanyl that may be fatal. Avoid exposing the DURAGESIC application site and surrounding area to direct external heat sources, such as heating pads or electric blankets, heat or tanning lamps, saunas, hot tubs, and heated water beds, while wearing the system. Avoid taking hot baths or sunbathing. There is a potential for temperature-dependent increases in fentanyl released from the system resulting in possible overdose and death. Patients wearing DURAGESIC systems who develop fever or increased core body temperature due to strenuous exertion should be monitored for opioid side effects and the DURAGESIC dose should be adjusted if necessary and hydromorphone.
Prescription for Survival of a Medical Society in the 21st Century Samuel S. Flint, PhD Fifty-four Years in Medicine Michael J. Franzblau, MD and ifosfamide.
Maximum daily dose of acetaminophen is 4 grams * Dosing guidelines are a guide for therapy. Dosing range is listed. Initial dosing should be individualized. Please do not order pain medication as a range order. Oral and Parenteral Opioid Analgesic Equivalencies and Relative Potency of Opioids as Compared with Morphine When converting from one opioid to another, you may use 50-75% of the equivalent dose. Allow for incomplete cross-tolerance between different opioids may need to titrate up rapidly and use prn dose to ensure effective analgesia for the first 24 hours ; . Avoid IM injection because of inconsistent absorption and patient discomfort. Opioid Agonists Parenteral mg ; Oral mg ; Duration of Effect DOSE CONVERSION GUIDELINES 1. Calculate the total daily dose of all opioids used. Morphine 10 30 3-4 hours 2. If the patient is taking more than one opioid, convert all agents to an equivalent dose of morphine. Oxycodone NA 20-30 3-4 hours 3. Determine equivalent dose of new opioid. Hydromorphone 1.5 7.5 3-4 hours 4. Initiate new opioid at 1 2 the calculated dose as tolerance is not complete from one opioid to another. Titrate up or down Meperidine 75 300 3 hours depending upon pain relief and development of side effects such as sedation ; Fentanyl 0.1 NA 1-2 hours 5. Provide for "rescue" doses. Each rescue should be 5-15% of the total daily maintenance dose and should be administered every 2-4 hours as needed for pain ; . Codeine 130 200 1-2 hours Hydrocodone NA 25-30 3.5 hours These are rough approximations; individual patients may vary. Meperidine is not a first line opioid. It should not be used longer than 48 hours or more than 600mg 24 hours. Parenteral opiate: onset of action, 5 min; peak, 15 min Oral opiate: onset of action, 15-30 min; peak, 45-60 min.
Biological Results The activities of the novel 3, 5-disubstituted hydantoins 5a-h were evaluated against herpes simplex virus-1 HSV-1 KOS strain ; , herpes simplex virus-2 HSV-2 strain G ; , herpes simplex virus-1 ACVresistant KOS strain ; , vaccinia virus, vesicular stomatitis virus, Coxsackie virus B4, respiratory syncytial virus, parainfluenza-3 virus, reovirus-1, Sindbis virus and Punta Toro virus. These activities were compared with those of acyclovir, ganciclovir and ribavirin Table 4 ; . Table 4. Antiviral activity of the novel 3, 5-disubstituted hydantoins 5a-h and iloprost.
Intoxicants or drugs in the workplace. An employee will not be tested under this paragraph unless employee conduct or other related circumstances provide a reasonable basis to believe that the employee may have ingested an intoxicating substance and or is suffering from impairment of some sort. Such observation must be confirmed by a second person such as a supervisor, occupational health and safety professional, or similarly trained individual wherever possible. 3 ; Post-Accident Incident: Any and all employees who are involved in an on-thejob accident or incident which involves use of vehicular equipment, heavy equipment, power tools or other dangerous instrumentality or working conditions and which results in a lost time injury or property damage generally in excess of , 000 ; shall be referred for a substance test unless a XXXXXX safety representative determines that the employee did not contribute to the cause of the accident or could not have avoided it. Employees shall be tested as soon as possible but no later than the end of the workday. 4 ; Employees removed from duty for reasonable cause or post-accident testing will remain off duty, until confirmatory test results are received. If the employee tests negatively, the employee will be paid for the time missed. If the employee's confirmatory test and MRO review result in a final positive determination, the employee will be barred from the workplace effective the date and time of the specimen collection. Any employee so barred may be eligible for reemployment after a period of not less than sixty days. Before being rehired, any such employee must pass a drug test conducted by XXXXXX at the employee's expense and must agree, as a condition of reemployment, to submit to accelerated random substance use testing at XXXXXX's request, for a period of six months. D. Drugs To Be Tested And Test Procedures a. Test Procedures: Testing procedures, including drugs to be tested, specimen collection, chain of custody and threshold and confirmation test levels shall comport guidelines established herein by XXXXXX. Confirmatory drug tests shall be conducted only by certified or licensed laboratories. Test Procedures: At the current time testing for the following drugs utilizing an immunoassay screening methodology and confirmed by gas chromatography mass spectrometry GC MS ; or its equivalent. THC delta-9-tetrahydrocannabinol ; Opiates Morphine, Heroin, 6am, codeine, dihydrocodeine, oxycodone, oxymorphone, hydrocodone, hydromorphone ; Methamphetamine d-methamaphetamine, MDMA Ecstasy ; Cocaine cocaine, benzyclonine ; ALCOHOL - Alcohol tests shall be initially by breath or Oral fluid Alcohol on-site screens. Additional testing, if required, shall be at a designated testing facility by a qualified BAT technician. Any test revealing an alcohol level equal to or greater than 0.05 percent and the individual shall not be allowed to return to work that day. A level above 0.08 percent shall be considered abuse and hydroxychloroquine.
|
